Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment.
The clinical manifestations, differential diagnosis, and treatment of the neuroleptic malignant syndrome and neuroleptic-induced catatonia are discussed. A case is presented in which the catatonic-like behavior and extrapyramidal sequelae of the neuroleptic malignant syndrome responded to combined treatment with anticholinergics and levodopa/carbidopa. Differential diagnosis and theories regarding the development of these neuroleptic-induced disorders are reviewed.
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000188:drug therapy; D002230:Carbidopa / Q000008:administration & dosage; D002389:Catatonia / Q000139:chemically induced* / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D006220:Haloperidol / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D013577:Syndrome; D014282:Trihexyphenidyl / Q000008:administration & dosage
D014150:Antipsychotic Agents; D007980:Levodopa; D014282:Trihexyphenidyl; D006220:Haloperidol; D002230:Carbidopa